Tenderwize
Wróć do wyszukiwania

Open house discount agreements for iron(III)hydroxide-polymaltose complex, ATC B03AC01

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 05, 2027 · 249 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Eisen(III)hydroxid-Polymaltose-Komplex, ATC B03AC01

50/100

Ocena szansy

PromisingLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

30 / 100

Czynniki ryzyka

No guaranteed purchase volume or minimum order quantity; revenue depends on actual prescriptions and market share.

Open-house agreements may be overridden by future formal framework contracts (bundesweit oder landesspezifisch) for the...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Strong opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply of pharmaceutical products containing iron(III)hydroxide-polymaltose complex (ATC B03AC01) to AOK Bayern insured persons
  • Conclusion of non-exclusive discount agreements (rabattverträge) under §130a(8) SGB V
Pokaż pełne podsumowanie

The AOK Bayern (Bavaria Health Insurance) is conducting an open-house model for non-exclusive discount agreements on pharmaceutical products containing iron(III)hydroxide-polymaltose complex (ATC B03AC01) under §130a(8) SGB V. This is not a typical procurement procedure; any interested pharmaceutical company meeting eligibility criteria can sign identical, non-negotiable agreements. Contracts have a fixed end date of 30 June 2027, with possible start from 1 July 2025. The open-house is open until 5 May 2027. No estimated contract value is provided. The process is governed by German social law, not procurement law. Submission can be in paper form (hand-signed) or electronically with a qualified electronic signature. Only pharmaceutical companies can participate.

Ryzyka

No guaranteed purchase volume or minimum order quantity; revenue depends on actual prescriptions and market share.

Open-house agreements may be overridden by future formal framework contracts (bundesweit oder landesspezifisch) for the...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Only pharmaceutical companies (pharmazeutische Unternehmen) can participate

Administrative

  • Submission of signed contract, completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
  • Hand-signed paper documents in duplicate OR electronically with qualified electronic signature via the communication area of the dtvp portal

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria; participation is open to all qualified pharmaceutical companies.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open house discount agreements for iron(III)hydroxide-polymaltose complex, ATC B03AC01

Non-exclusive discount agreements for the active ingredient iron(III)hydroxide-polymaltose complex (ATC B03AC01). Contracts are identical for all participants, no individual negotiation. Performance location: Bavaria, Germany. Contract period: 1 July 2025 to 30 June 2027. Early termination possible with one month notice. Agreements automatically superseded if a nationwide or state-specific framework discount contract for the same active ingredient is concluded via a formal procedure.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Jun 2025 - Jun 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria; participation is open to all qualified pharmaceutical companies.

Termin

Deadline May 05, 2027

Szczegóły zamówienia

Data publikacji
15 May 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
315689-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30